NASDAQ:ERNA Ernexa Therapeutics 11/12/2024 Earnings Report $1.70 +0.05 (+3.19%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$1.68 -0.01 (-0.88%) As of 08/8/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Ernexa Therapeutics EPS ResultsActual EPS-$73.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AErnexa Therapeutics Revenue ResultsActual Revenue$0.49 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AErnexa Therapeutics Announcement DetailsQuarterDate11/12/2024TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsErnexa Therapeutics' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Ernexa Therapeutics Earnings HeadlinesErnexa Therapeutics Regains Compliance with Nasdaq for Continued ...July 11, 2025 | nasdaq.comErnexa Therapeutics Regains Compliance with Nasdaq ... - MorningstarJuly 11, 2025 | morningstar.comMThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 9 at 2:00 AM | Weiss Ratings (Ad)Ernexa Therapeutics Regains Compliance with Nasdaq Listing RequirementsJuly 9, 2025 | globenewswire.comErnexa Therapeutics changes independent auditor to Haskell & WhiteJuly 8, 2025 | investing.comErnexa Therapeutics Expands Scientific Advisory Board as It Prepares for Clinical Trials in Ovarian Cancer and Autoimmune Disease - NasdaqJune 27, 2025 | nasdaq.comSee More Ernexa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ernexa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ernexa Therapeutics and other key companies, straight to your email. Email Address About Ernexa TherapeuticsEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.View Ernexa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Airbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a Rally Upcoming Earnings SEA (8/12/2025)Cisco Systems (8/13/2025)Alibaba Group (8/13/2025)NetEase (8/14/2025)Applied Materials (8/14/2025)Petroleo Brasileiro S.A.- Petrobras (8/14/2025)NU (8/14/2025)Deere & Company (8/14/2025)Palo Alto Networks (8/18/2025)Medtronic (8/19/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
